## MOH: Molina Healthcare Inc - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 8.6% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($155.20)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Molina Healthcare, Inc. (MOH) and Encourages Stockholders to Learn More About the Investigation**
- Source: mypanhandle.com | 20251209T160829 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Molina Healthcare, Inc. (MOH) for potential corporate wrongdoing. The firm is encouraging stockholders who purchased Molina securities before February 5, 2025, and still hold them, to contact them for more information and to assist with the investigation. The investigation aims to determine if Molina and its officers/directors engaged in any misconduct.

**2. Molina Healthcare, Inc. (MOH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation**
- Source: CBS 42 | 20251211T160833 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Molina Healthcare, Inc. (MOH) regarding potential corporate wrongdoing. The firm is encouraging stockholders who purchased Molina securities before February 5, 2025, and still hold them, to contact them to learn more and assist with the investigation. This action is part of the firm's practice of representing investors in securities fraud class actions on a contingency fee basis.

**3. Molina Healthcare, Inc. (MOH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation**
- Source: MyWabashValley.com | 20251211T160822 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molina Healthcare, Inc. (MOH) securities. The firm encourages stockholders who purchased Molina securities prior to February 5, 2025, and still hold them, to contact their firm to learn more about the investigation into potential corporate wrongdoing by Molina and its officers/directors.

**4. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Molina Healthcare, Inc. (MOH) and Encourages Stockholders to Learn More About the Investigation**
- Source: WJBF | 20251209T160815 | Neutral | Relevance: 98%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Molina Healthcare, Inc. (MOH) concerning potential corporate wrongdoing by its officers and/or directors. The firm encourages stockholders who purchased Molina securities prior to February 5, 2025, and still hold them, to contact them for more information and to assist with the investigation. This investigation is being conducted on a contingency fee basis.

**5. Is Molina Healthcare Stock Underperforming the Dow?**
- Source: Markets Financial Content | 20251211T084200 | Neutral | Relevance: 98%
-  Molina Healthcare, Inc. (MOH), a mid-cap company providing managed healthcare services, has seen its stock drop significantly, underperforming the Dow Jones Industrials Average ($DOWI). The company's shares are down 55.4% from their 52-week high, 10.4% over three months, and 44.9% year-to-date, largely due to elevated medical costs and a reduced full-year profit forecast. Analysts hold a "Hold" rating on MOH stock, with a mean price target representing a modest premium to current levels.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-12 | Wells Fargo | $165 | $231 | -29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-12 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.44M) |
| Sells | 1 ($0.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.1%)
- Capital World Invest: 9.5% (-2.0%)
- Blackrock Inc.: 8.4% (-3.9%)
- Price (T.Rowe) Assoc: 6.5% (+58.8%)
- AQR Capital Manageme: 5.4% (+217.0%)

### Key Risks

1. Elevated short interest (11.4%): bears positioning against stock.
2. Long-term trend broken: trading 28.8% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +7.2% over 5 days suggests accumulation.

### Fundamentals

Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.0B |
| Beta | 0.52 |
| 52W Range | $133.40 - $359.97 |
| Short Interest | 11.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.62 |
| Forward P/E | 11.9 |
| Current P/E | 11.8 |
| YoY Growth | -0.8% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from 1.4% to 8.6% (+7.2% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (8.6% > 6.0%), caution on chasing. MRS_5 at 5.4% confirms short-term momentum alignment. Outperforming sector by 10.9pp, stock-specific strength. Below SMA200 (0.71x), long-term trend not supportive. MACD histogram positive (3.51), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 8.61% (CS: 96) | Strong |
| RSI_14 | 66.3 | Neutral |
| MACD Histogram | 3.51 | Bullish |
| vs SMA20 | 1.136x | Above |
| vs SMA50 | 1.021x | Above |
| vs SMA200 | 0.712x | Below |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $166.90
- **Stop Loss:** $155.20 (7.0% risk)
- **Target:** $178.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 117
- **Position Value:** $19,527.30
- **Portfolio %:** 19.53%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-04 (Est: $0.64)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.89 | $1.84 | -52.7% |
| 2025Q2 | $5.53 | $5.48 | -0.9% |
| 2025Q1 | $5.96 | $6.08 | +2.0% |
| 2024Q4 | $5.88 | $5.05 | -14.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*